A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

Background: Genetic alterations in fibroblast growth factor receptors 2 and 3 (FGFR2/3) occur in nearly all cancer types.FGFR2 fusions and rearrangements occur in up to 10-15% of intrahepatic ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Consistent with previously published reports for mNSCLC, PD-L1 expression enriched for 1L anti-PD-1 + PDCT benefit in NSQ but not SQ tumors (CheckMate 227 Part 2). Differences in LAG-3 ligand ...

GSK Stops Phase 3 Trial Evaluating Tebipenem HBr. Published: May 28, 2025 at 7:31 a.m. ET. Share. Resize. About Dow Jones Newswires. Dow Jones Newswires is a market-moving financial and business ...

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking approval of its investigational ileal bile acid transporter (“IBAT”) ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout. The trial of 1,690 hospitalized patients with ...